Show/hide main menu

Professor Ellen Solomon



  • Mays AN, Osheroff N, Xiao Y, Wiemels JL, Felix CA, Byl JAW, Saravanamuttu K, Pennikey A, Corser R, Chang C, Hoyle C, Parker AN, Hasan SK, Lo-Coco F, Solomon E and Grimwade D (2010). Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia. Blood 115: 326-30.


  • Brown NJM, Ramalho M, Pedersen EW, Moravcsik E, Solomon E and Grimwade D (2009). PML nuclear bodies in the pathogenesis of acute promyelocytic leukemia: active players or innocent bystanders? Frontiers in Bioscience 14: 1684-707.
  • Grimwade D, Jovanovic JV, Hills RK, Nugent EA, Patel Y, Flora R, Diverio D, Jones K, Aslett H, Batson E, Rennie K, Angell R, Clark RE, Solomon E, Lo-Coco F, Wheatley K and Burnett AK (2009). Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. Journal of Clinical Oncology 27: 3650-8.
  • Morris JR, Boutell C, Keppler M, Densham R, Weekes D, Alamshah A, Butler L, Galanty Y, Pangon L, Kiuchi T, Ng T and Solomon E (2009). The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress. Nature 462: 886-90.
  • Waters S, Marchbank K, Solomon E, Whitehouse C and Gautel M (2009). Interactions with LC3 and polyubiquitin chains link nbr1 to autophagic protein turnover. FEBS Letters 583: 1846-52.


  • Alamshah A, Springall R, Gillett CE, Solomon E and Morris JR (2008). Use of a BRCA1 peptide validates MS110 as a BRCA1-specific antibody in immunohistochemistry. Histopathology 53: 117-20.


  • Barwell J, Pangon L, Georgiou A, Kesterton I, Langman C, Arden-Jones A, Bancroft E, Salmon A, Locke I, Kote-Jarai Z, Morris JR, Solomon E, Berg J, Docherty Z, Camplejohn R, Eeles R and Hodgson SV (2007). Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility. International Journal of Cancer 121: 1631-6.
  • Barwell J, Pangon L, Hodgson S, Georgiou A, Kesterton I, Slade T, Taylor M, Payne SJ, Brinkman H, Smythe J, Sebire NJ, Solomon E, Docherty Z, Camplejohn R, Homfray T and Morris JR (2007). Biallelic mutation of MSH2 in primary human cells is associated with sensitivity to irradiation and altered RAD51 foci kinetics. Journal of Medical Genetics 44: 516-20.
  • Deguara J, Burnand KG, Berg J, Green P, Lewis CM, Chinien G, Waltham M, Taylor P, Stern RF, Solomon E and Smith A (2007). An increased frequency of the 5A allele in the promoter region of the MMP3 gene is associated with abdominal aortic aneurysms. Human Molecular Genetics 16: 3002-7.
  • Guidez F, Parks S, Wong H, Jovanovic JV, Mays A, Gilkes AF, Mills KI, Guillemin M-C, Hobbs RM, Pandolfi PP, de The H, Solomon E and Grimwade D (2007). RARalpha-PLZF overcomes PLZF-mediated repression of CRABPI, contributing to retinoid resistance in t(11;17) acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America 104: 18694-9.
  • Jovanovic JV, Score J, Waghorn K, Cilloni D, Gottardi E, Metzgeroth G, Erben P, Popp H, Walz C, Hochhaus A, Roche-Lestienne C, Preudhomme C, Solomon E, Apperley J, Rondoni M, Ottaviani E, Martinelli G, Brito-Babapulle F, Saglio G, Hehlmann R, Cross NCP, Reiter A and Grimwade D (2007). Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 109: 4635-40.


  • Lovelock PK, Healey S, Au W, Sum EYM, Tesoriero A, Wong EM, Hinson S, Brinkworth R, Bekessy A, Diez O, Izatt L, Solomon E, Jenkins M, Renard H, Hopper J, Waring P, Investigators k, Tavtigian SV, Goldgar D, Lindeman GJ, Visvader JE, Couch FJ, Henderson BR, Southey M, Chenevix-Trench G, Spurdle AB and Brown MA (2006). Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants. Journal of Medical Genetics 43: 74-83.
  • Morris JR, Pangon L, Boutell C, Katagiri T, Keep NH and Solomon E (2006). Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility. Human Molecular Genetics 15: 599-606.


  • Gale RE, Hills R, Pizzey AR, Kottaridis PD, Swirsky D, Gilkes AF, Nugent E, Mills KI, Wheatley K, Solomon E, Burnett AK, Linch DC, Grimwade D and Party NALW (2005). Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood 106: 3768-7376.
  • Jefferies S, Kote-Jarai Z, Goldgar D, Houlston R, Frazer-Williams MJ, A'Hern R, Collaborators MPT, Eeles R, Henk J, Gore M, Rhys-Evans P, Archer D, Bishop K, Solomon E, Hodgson S, McGurk M, Hibbert J, O'Connell M, Partridge M, Chevretton E, Calman F, Saunders M, Shotton K, Brown A, Whittaker S and Foulkes W (2005). Association between polymorphisms of the GPX1 gene and second primary tumours after index squamous cell cancer of the head and neck. Oral Oncology 41: 455-61.
  • Mistry AR, Felix CA, Whitmarsh RJ, Mason A, Reiter A, Cassinat B, Parry A, Walz C, Wiemels JL, Segal MR, Ades L, Blair IA, Osheroff N, Peniket AJ, Lafage-Pochitaloff M, Cross NCP, Chomienne C, Solomon E, Fenaux P and Grimwade D (2005). DNA topoisomerase II in therapy-related acute promyelocytic leukemia. New England Journal of Medicine 352: 1529-38.
Sitemap Site help Terms and conditions  Privacy policy  Accessibility  Modern slavery statement  Contact us

© 2023 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454